Inactive Instrument

News Lifestyle Delivery Systems Inc Canadian Securities Exchange

Equities

CA53224Y1043

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Core One Labs : Announces Non-Brokered Private Placement	Apr. 09	PU
Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding	Apr. 08	CI
Core One Labs Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 29	CI
Core One Labs Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 03	CI
Core One Labs Inc. announced that it has received CAD 0.2 million in funding	23-09-17	CI
Core One Labs : Announces Non-Brokered Private Placement	23-09-11	PU
Core One Labs Inc. announced that it expects to receive CAD 1 million in funding	23-09-10	CI
Core One Labs Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-28	CI
Core One Labs : Commends Study Exploring Psychedelics’ Efficacy in Providing Relief for Chronic Pain Conditions	23-08-23	PU
Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer?s and Parkinson's Disease	23-08-04	CI
Core One Labs : Applauds Groundbreaking Research on Psilocybin as a Potential Anorexia Treatment	23-08-03	PU
Core One Labs Inc. Reports Earnings Results for the Fifteen Months Ended March 31, 2023	23-08-03	CI
Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer?s and Parkinson?s Disease	23-07-28	CI
Core One Labs : Applauds California Assembly Health Committee’s Approval of Bill to Legalize Psychedelics	23-07-19	PU
Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process	23-07-12	MT
Core One's Vocan Files International Patent For Breakthrough Proprietary Biosynthetic Psilocybin Production Method	23-07-10	MT
Core One Labs Inc. Applauds FDA's Draft Guidance on Clinical Trials for Psychedelic Drugs	23-06-27	CI
Core One Labs : Applauds FDA’s Draft Guidance on Clinical Trials for Psychedelic Drugs	23-06-26	PU
Core One Labs Says in Talks with Multiple Companies to Supply Psilocybin; COOL Gained 15% on Friday	23-05-08	MT
Core One Labs Inc. in Talks with Multiple Companies to Supply Psilocybin	23-05-05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Lifestyle Delivery Systems Inc Canadian Securities Exchange

Equities

CA53224Y1043

Summary

Filters